Financial Performance - The company achieved total operating revenue of CNY 195,132,408.42, representing a year-on-year increase of 1.66%[5] - Net profit attributable to shareholders reached CNY 40,295,863.91, a significant increase of 76.11% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 37,159,179.32, up 74.52% year-on-year[5] - Basic earnings per share increased to CNY 0.79, reflecting a growth of 31.67%[5] Assets and Equity - Total assets at the end of the reporting period were CNY 417,656,757.08, an increase of 11.19% year-on-year[5] - Shareholders' equity attributable to the company was CNY 365,890,374.70, up 9.62% from the previous year[5] Product Performance - Hearing aid products accounted for over 90% of total revenue, with a notable increase in the sales of high-margin digital hearing aids[5] Foreign Exchange Impact - The company benefited from foreign exchange gains due to the appreciation of the US dollar, which positively impacted profit margins[5] Future Plans - The company plans to continue increasing R&D investment to enhance product offerings and profitability[5] Cautionary Note - The financial data presented is preliminary and has not been audited, cautioning investors to be aware of potential risks[6]
锦好医疗(872925) - 2022 Q4 - 年度业绩